


Figure 2. Reasons for subcutaneous infliximab treatment discontinuation.



*Adverse events leading to treatment discontinuation were rash (n=3), local reactions (n=1), general symptoms (a sense of balance difficulty and dizziness, n=1), and neutropenia (n=1).